ASH 2021 | Effects of lenalidomide maintenance therapy and the immune microenvironment in patients with myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses a study which investigated the role of the immune microenvironment in multiple myeloma (MM) patients treated with lenalidomide maintenance therapy, and how this impacted sustained minimal residual disease (MRD) negativity. Dr Landgren explains some interesting results from this study, which showed that the microenvironment of patients who obtained a sustained deep response was different from the microenvironment of those who lost MRD status or did not achieve a deep response. Dr Landgren also discusses the effects of lenalidomide maintenance therapy on microenvironment, and compares this to healthy individuals, patients with monoclonal gammopathy of undetermined significance (MGUS), and patients with smoldering myeloma. To conclude, Dr Landgren emphasizes the importance of this data and how it can be used to improve the future of myeloma therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
